The molecular genetics of Alport syndrome: report of two workshops

Alport syndrome (AS), a hereditary nephritis progressing to end stage renal failure in males, with sensorineural deafness, anterior lenticonus, and macular flecks, represents a significant medicoeconomic burden. Molecular genetics has now begun to unravel its complexities, although these are still far from resolved.

Two recent international workshops have discussed the latest developments. Last August, a meeting at Oulu (International Workshop on Alport’s Syndrome, Oulu, Finland, 22 to 24 August 1991) set out to draw meaningful correlations between the different mutations characterised to date and the resulting phenotypes, and this was followed in October by a further workshop in Washington, DC (Workshop on Hereditary Kidney Disease, 8th International Congress of Human Genetics, Washington DC, October 1991).

Investigation of AS has not been straightforward. Over 50 years ago Alport described a three generation family with haematuria and deafness, showing most signs of the syndrome later named after him, and several large kindreds have subsequently been described, with varying patterns of inheritance.

Three groups independently localised the AS gene to Xq21–q22. AS had long been thought to affect primarily basement membrane collagen, as the glomerular basement membrane (GBM) in AS is grossly disordered. GBM mainly consists of collagen type IV, but the two component chains identified first (α1(IV) and α2(IV)) mapped to chromosome 13. Only later did it emerge that other rare chains were involved in collagen IV, and not until 1990 was one of these, α5(IV), independently cloned by two groups from Oulu and the gene mapped to the AS region on the X chromosome.

Tryggvason and his international collaborators then clinched matters by reporting mutations in the α5(IV) gene in three AS kindreds. Details of 30 or so independent mutations which have been characterised by several groups to date were presented at Oulu. The organisers aimed to correlate these different mutations with the resulting phenotype, and this led to the establishment of an international consortium to exchange information on the gene and its mutants.

Following Oulu, the Washington workshop covered a number of other disorders, including polycystic kidney disease, Lowe syndrome, and von Hippel-Lindau disease, but Alport syndrome received substantial attention. One interesting subject raised was the immune response to renal transplantation; 14 AS patients who developed anti-GBM antibodies leading to graft rejection have now been reported. Kashlan (Minneapolis) postulated that major rearrangements within the α5(IV) gene might be more likely to lead to anti-GBM nephritis, with subsequent graft rejection, but this is not yet clear. A further complicating factor was discussed by Hudson (Kansas), who presented his findings on the specificity of anti-GBM antibodies elicited from an AS patient’s rejected graft. The alloantibodies reacted mainly with dimer subunits of the NCI domain of collagen IV, identical to those reacting with Goodpasture (GP) antibodies, and have been chemically identified as derived from the α3 chain of collagen IV (mapped to chromosome 2). This means that GBM collagen antigenicity is altered in some AS patients, which may reflect either the absence of the α3 chain, or the exposure of a new structural epitope on this chain. These findings, together with evidence that some AS patients fail to bind the GP antibody in their native kidneys, and that anti-basement membrane autoantibodies produced by GP patients sometimes fail to stain glomeruli in AS kidneys, strongly suggest that the α3 chain, as well as the newly characterised α5 chain, is involved in the primary pathology.

‘Alport syndrome’ has been used to label many sorts of hereditary nephritis, and some remarkably imaginative theories of inheritance have been put forward. Barker (Salt Lake City) dismissed some of these, and reviewed others, at the Oulu workshop. There has been no general agreement on the frequency of autosomal versions, if indeed they exist. The main question is: are all X linked cases attributable to the α5(IV) gene locus, or is there another type IV collagen gene on the X chromosome? Also at Oulu, Tryggvason presented the most persuasive hint yet that a second X linked gene exists, a family with a mutation in the X linked gene but with no hearing impairment. The basement membrane collagen chain genes show interesting groupings: α1 and α2 map close together on chromosome 13° and α3 and α4 have now been mapped close together on 2q by Reeder (New Haven), who speculated that there may also be an undiscovered α6 on the X chromosome, close to α5.

Mapping and cloning genes generates publicity, but is only the first step towards understanding a gene’s function. Precise definition of mutations, the next step, brings immediate practical benefits, allowing precise carrier detection and prenatal diagnosis. In addition, defining individual mutations and correlating
them with the phenotype provides information on critical domains of the gene and its product, the tissues where it is expressed, and the range of effects of disordered gene function (different mutations presumably affecting the strength of the collagen network in different ways). The mass of new data arising from the two workshops has strengthened the idea that the connection between the apparently disparate organs affected may lie in the particular collagen chains from which they are constructed. Our knowledge will expand rapidly as more mutations causing AS are characterised. So far, it appears that only some 10 to 15% of mutations (mostly reported at Oulu) are the result of large, easily detectable gene rearrangements. Defining the rest will be less easy, although detailed information on cDNA sequence and genomic structure (Tryggvason, Oulu) allows 'mutation scanning' techniques such as chemical cleavage of mismatched DNA, denaturing gradient gel electrophoresis, single strand conformational polymorphism, or RNase cleavage to be used. These techniques compare the sequence of DNA under test with a control, and highlight any base mismatches for more detailed characterisation. Several groups are applying these to the AS gene, and the main long term benefit to emerge from these two meetings may be the international exchange of information on mutations as they are defined. The last three years have seen many significant advances in the understanding of the molecular pathology of AS, but important questions remain unanswered. Is AS one disorder or many? Eleven subtypes (discussed at Atkin, Salt Lake City, at Oulu) have been discerned, but whether these correspond to the effects of different genes, or allelic mutations in one gene, is unresolved. However, we should soon know if the 'splitters' or the 'lumpers' will carry the day.

FRANCES FLINTER
MARTIN BOBROW
Paediatric Research Unit,
Division of Medical and Molecular Genetics,
UMDS, Guy's Hospital,
London SE1 9RT.